A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers
This is a clinical trial of ponatinib that will be administered by mouth, which is investigational.
IRB Protocol #
ARIAD Pharmaceuticals, Inc.
BREANNA PRITCHARD at (720)848-0498 or BREANNA.PRITCHARD@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your disease does not worsen, you do not have severe side effects, and the study remains open. // Eligibility criteria include but are not limited to 18 years or older with lung cancer.Eligibility criteria include but are not limited to 18 years or older with lung cancer.